FDA Approves Once-Monthly Hereditary Angioedema Drug

(MedPage Today) -- Anti-factor XIIa biologic garadacimab (Andembry) got the FDA greenlight for use in preventing hereditary angioedema (HAE) attacks in adult and pediatric patients ages 12 years and older, CSL announced.
Garadacimab is the only...